A 28-year-old female with a family history of perioperative death (father died during anesthesia 15 years ago) is scheduled for elective laparoscopic appendicectomy. She is suspected to be at risk for malignant hyperthermia. Which investigation is most appropriate to confirm MH susceptibility preoperatively before she undergoes elective surgery?

Explanation

## Confirmatory Investigation for MH Susceptibility ### Gold Standard Diagnostic Test **Key Point:** The **caffeine halothane contracture test (CHCT)** on fresh muscle biopsy is the gold standard and most appropriate investigation to confirm malignant hyperthermia susceptibility in asymptomatic individuals with a family history. **High-Yield:** CHCT is the reference standard because it: - Directly tests muscle contractility in response to caffeine and halothane *ex vivo* - Has high sensitivity (~99%) and specificity (~94%) for MH susceptibility - Provides definitive classification: MH-susceptible (MHS), MH-equivocal (MHEh), or MH-normal (MHN) - Guides safe anesthetic management and family counseling - Is reproducible and standardized across specialized centers ### How CHCT Works 1. **Fresh muscle biopsy** obtained from vastus medialis or intercostal muscle 2. **Muscle strips** suspended in organ bath at 37°C 3. **Caffeine exposure** (2–4 mM) → sustained contracture in MHS patients 4. **Halothane exposure** (3%) → sustained contracture in MHS patients 5. **Threshold criteria** applied: - MHS: caffeine contracture ≥0.3 g AND halothane contracture ≥0.3 g - MHEh: one criterion met - MHN: neither criterion met ### Comparison of Diagnostic Approaches | Investigation | Sensitivity | Specificity | Timing | Utility | Limitations | |---|---|---|---|---|---| | **CHCT (gold standard)** | ~99% | ~94% | Weeks | Definitive diagnosis | Invasive, requires specialized lab | | **Genetic testing (RYR1, CACNA1S)** | ~70% | ~99% | Days | Supports diagnosis, family screening | Misses ~30% of MHS patients; variants of uncertain significance | | **Serum CK** | Low | Low | Hours | Baseline only | Nonspecific; normal in asymptomatic MHS | | **Core temperature** | None | None | Real-time | Monitoring only | Not diagnostic; rises late in crisis | **Clinical Pearl:** Genetic testing is increasingly used as a *complementary* tool, but it does not replace CHCT because: - Pathogenic variants in RYR1 and CACNA1S account for ~70% of MHS cases - Many MHS individuals have no identified mutation (genotype-negative, phenotype-positive) - Variants of uncertain significance cannot definitively predict MH risk ### Preoperative Management Based on CHCT Results ```mermaid flowchart TD A[Suspected MH susceptibility]:::outcome --> B[CHCT performed]:::action B --> C{CHCT Result}:::decision C -->|MHS| D[Avoid triggering agents<br/>Use TIVA + non-depolarizing agents]:::action C -->|MHEh| E[Counsel patient<br/>Precautions advised]:::action C -->|MHN| F[Standard anesthesia safe<br/>No precautions needed]:::action D --> G[Dantrolene standby<br/>Inform family]:::action E --> H[Genetic counseling<br/>Family screening considered]:::action ``` **Mnemonic: CHCT-MHS** — Caffeine Halothane Contracture Test for Malignant Hyperthermia Susceptibility ### Why Other Options Are Incorrect - **Serum CK:** Baseline CK is often normal in asymptomatic MHS individuals. It is not diagnostic and does not guide preoperative management. CK rises only during or after an acute MH crisis. - **Resting core temperature:** Temperature monitoring is useful *during* anesthesia to detect MH crisis, but baseline temperature is normal in MHS patients and cannot diagnose susceptibility. - **Genetic testing alone:** While RYR1 and CACNA1S mutations are found in ~70% of MHS patients, genetic testing does not replace CHCT. It cannot rule out MH susceptibility in mutation-negative individuals (phenotype-positive, genotype-negative MHS exists). [cite:Miller's Anesthesia 8e Ch 27; Malignant Hyperthermia Association Guidelines]